{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:30Z","timestamp":1792525590581,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI136443"],"award-info":[{"award-number":["U19 AI136443"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00281-021-00849-w","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T23:19:28Z","timestamp":1619306368000},"page":"459-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lessons learned from targeting eosinophils in human disease"],"prefix":"10.1007","volume":"43","author":[{"given":"Fei Li","family":"Kuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-6009","authenticated-orcid":false,"given":"Bruce S.","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"849_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","volume":"24","author":"ME Rothenberg","year":"2006","unstructured":"Rothenberg ME, Hogan SP (2006) The eosinophil. Annu Rev Immunol 24:147\u2013174","journal-title":"Annu Rev Immunol"},{"key":"849_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/mi.2015.2","volume":"8","author":"J Travers","year":"2015","unstructured":"Travers J, Rothenberg ME (2015) Eosinophils in mucosal immune responses. Mucosal Immunol 8:464\u2013475","journal-title":"Mucosal Immunol"},{"key":"849_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri3341","volume":"13","author":"HF Rosenberg","year":"2013","unstructured":"Rosenberg HF, Dyer KD, Foster PS (2013) Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13:9\u201322","journal-title":"Nat Rev Immunol"},{"key":"849_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","volume":"15","author":"AD Klion","year":"2020","unstructured":"Klion AD, Ackerman SJ, Bochner BS (2020) Contributions of eosinophils to human health and disease. Annu Rev Pathol 15:179\u2013209","journal-title":"Annu Rev Pathol"},{"key":"849_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/367183a0","volume":"367","author":"AS Gounni","year":"1994","unstructured":"Gounni AS, Lamkhioued B, Ochial K, Tanaka Y, Delaporte E, Capron A, Kinet JP, Capron M (1994) High-affinity IgE receptor on eosinophils is involved in defense against parasites. Nature 367:183\u2013186","journal-title":"Nature"},{"key":"849_CR6","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.4049\/jimmunol.162.11.6901","volume":"162","author":"H Kita","year":"1999","unstructured":"Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, Gleich GJ (1999) Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 162:6901\u20136911","journal-title":"J Immunol"},{"key":"849_CR7","doi-asserted-by":"crossref","unstructured":"Seminario M-C, Saini SS, MacGlashan DW Jr, Bochner BS (1999) Intracellular expression and release of Fc\u03b5RI\u03b1 by human eosinophils. J Immunol 162:6893\u20136900","DOI":"10.4049\/jimmunol.162.11.6893"},{"key":"849_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0091-6749(00)90081-2","volume":"105","author":"SJ Smith","year":"2000","unstructured":"Smith SJ, Ying S, Meng Q, Sullivan MH, Barkans J, Kon OM, Sihra B, Larche M, Levi-Schaffer F, Kay AB (2000) Blood eosinophils from atopic donors express messenger RNA for the alpha, beta, and gamma subunits of the high-affinity IgE receptor (Fc epsilon RI) and intracellular, but not cell surface, alpha subunit protein. J Allergy Clin Immunol 105:309\u2013317","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2222.2010.03484.x","volume":"40","author":"JJ Lee","year":"2010","unstructured":"Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA (2010) Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 40:563\u2013575","journal-title":"Clin Exp Allergy"},{"key":"849_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2012.07.025","volume":"130","author":"JJ Lee","year":"2012","unstructured":"Lee JJ, Jacobsen EA, Ochkur SI, McGarry MP, Condjella RM, Doyle AD, Luo H, Zellner KR, Protheroe CA, Willetts L, Lesuer WE, Colbert DC, Helmers RA, Lacy P, Moqbel R, Lee NA (2012) Human versus mouse eosinophils: \"that which we call an eosinophil, by any other name would stain as red\". J Allergy Clin Immunol 130:572\u2013584","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/JLB.1MR1117-442RR","volume":"104","author":"H Abdala-Valencia","year":"2018","unstructured":"Abdala-Valencia H, Coden ME, Chiarella SE, Jacobsen EA, Bochner BS, Lee JJ, Berdnikovs S (2018) Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J Leukoc Biol 104:95\u2013108","journal-title":"J Leukoc Biol"},{"key":"849_CR12","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1084\/jem.20172049","volume":"215","author":"IC Arnold","year":"2018","unstructured":"Arnold IC, Artola-Boran M, Tallon de Lara P, Kyburz A, Taube C, Ottemann K, van den Broek M, Yousefi S, Simon HU, Muller A (2018) Eosinophils suppress Th1 responses and restrict bacterially induced gastrointestinal inflammation. J Exp Med 215:2055\u20132072","journal-title":"J Exp Med"},{"key":"849_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1126\/science.1099472","volume":"305","author":"JJ Lee","year":"2004","unstructured":"Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O'Neill KR, Protheroe C, Pero R, Nguyen T, Cormier SA, Lenkiewicz E, Colbert D, Rinaldi L, Ackerman SJ, Irvin CG, Lee NA (2004) Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305:1773\u20131776","journal-title":"Science"},{"key":"849_CR14","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1126\/science.1100283","volume":"305","author":"AA Humbles","year":"2004","unstructured":"Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, Ghiran S, Gerard NP, Yu C, Orkin SH, Gerard C (2004) A critical role for eosinophils in allergic airways remodeling. Science 305:1776\u20131779","journal-title":"Science"},{"key":"849_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.immuni.2014.02.014","volume":"40","author":"VT Chu","year":"2014","unstructured":"Chu VT, Beller A, Rausch S, Strandmark J, Zanker M, Arbach O, Kruglov A, Berek C (2014) Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity 40:582\u2013593","journal-title":"Immunity"},{"key":"849_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ni.1981","volume":"12","author":"VT Chu","year":"2011","unstructured":"Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, Lee JJ, Lohning M, Berek C (2011) Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 12:151\u2013159","journal-title":"Nat Immunol"},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"557960","DOI":"10.3389\/fimmu.2020.557960","volume":"11","author":"RD FitzPatrick","year":"2020","unstructured":"FitzPatrick RD, Kennedy MHE, Lawrence KM, Gauthier CM, Moeller BE, Robinson AN, Reynolds LA (2020) Littermate-controlled experiments reveal eosinophils are not essential for maintaining steady-state IgA and demonstrate the influence of rearing conditions on antibody phenotypes in eosinophil-deficient mice. Front Immunol 11:557960","journal-title":"Front Immunol"},{"key":"849_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","volume":"68","author":"SCS Simon","year":"2019","unstructured":"Simon SCS, Utikal J, Umansky V (2019) Opposing roles of eosinophils in cancer. Cancer Immunol Immunother 68:823\u2013833","journal-title":"Cancer Immunol Immunother"},{"key":"849_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1172\/JCI19133","volume":"113","author":"JY Cho","year":"2004","unstructured":"Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Friedman S, Broide DH (2004) Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 113:551\u2013560","journal-title":"J Clin Invest"},{"key":"849_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1172\/JCI17974","volume":"112","author":"P Flood-Page","year":"2003","unstructured":"Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB (2003) Anti-IL-5 treatment reduces deposition of extracellular matrix proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029\u20131036","journal-title":"J Clin Invest"},{"key":"849_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2010.02.026","volume":"126","author":"BS Bochner","year":"2010","unstructured":"Bochner BS, Gleich GJ (2010) What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol 126:16\u201325","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/all.12169","volume":"68","author":"GJ Gleich","year":"2013","unstructured":"Gleich GJ, Klion AD, Lee JJ, Weller PF (2013) The consequences of not having eosinophils. Allergy 68:829\u2013835","journal-title":"Allergy"},{"key":"849_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coph.2019.01.002","volume":"46","author":"D Simon","year":"2019","unstructured":"Simon D, Simon HU (2019) Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol 46:29\u201333","journal-title":"Curr Opin Pharmacol"},{"key":"849_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1067\/mai.2003.1382","volume":"111","author":"A Menzies-Gow","year":"2003","unstructured":"Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111:714\u2013719","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","volume":"3","author":"F Legrand","year":"2015","unstructured":"Legrand F, Klion AD (2015) Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract 3:167\u2013174","journal-title":"J Allergy Clin Immunol Pract"},{"key":"849_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fmed.2018.00049","volume":"5","author":"F Roufosse","year":"2018","unstructured":"Roufosse F (2018) Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne) 5:49","journal-title":"Front Med (Lausanne)"},{"key":"849_CR27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","volume":"125","author":"WW Busse","year":"2010","unstructured":"Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA (2010) Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 125:1237\u20131244","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR28","doi-asserted-by":"crossref","unstructured":"Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ (2010) MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125:1344\u20131353","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"849_CR29","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD (2019) Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med 380:1336\u20131346","journal-title":"N Engl J Med"},{"key":"849_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, Wenzel SE, Wilson AM, Small MB, Gopalan G, Ashton VL, Burden A, Hillyer EV, Kerkhof M, Pavord ID (2015) Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 3:849\u2013858","journal-title":"Lancet Respir Med"},{"key":"849_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0140-6736(19)33005-3","volume":"395","author":"MC Peters","year":"2020","unstructured":"Peters MC, Wenzel SE (2020) Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet 395:371\u2013383","journal-title":"Lancet"},{"key":"849_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973\u2013984","journal-title":"N Engl J Med"},{"key":"849_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651\u2013659","journal-title":"Lancet"},{"key":"849_CR34","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P, Investigators M (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198\u20131207","journal-title":"N Engl J Med"},{"key":"849_CR35","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators S (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189\u20131197","journal-title":"N Engl J Med"},{"key":"849_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, Zangrilli J, Garin M (2016) Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 150:799\u2013810","journal-title":"Chest"},{"key":"849_CR37","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390\u2013400","journal-title":"Lancet Respir Med"},{"key":"849_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M (2016) Reslizumab for Inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 150:789\u2013798","journal-title":"Chest"},{"key":"849_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","volume":"196","author":"EA Kelly","year":"2017","unstructured":"Kelly EA, Esnault S, Liu LY, Evans MD, Johansson MW, Mathur S, Mosher DF, Denlinger LC, Jarjour NN (2017) Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med 196:1385\u20131395","journal-title":"Am J Respir Crit Care Med"},{"key":"849_CR40","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V, Goldman M, investigators Ss (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115\u20132127","journal-title":"Lancet"},{"key":"849_CR41","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkstrom V, Aurivillius M, Goldman M, investigators Cs (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388:2128\u20132141","journal-title":"Lancet"},{"key":"849_CR42","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","volume":"5","author":"GT Ferguson","year":"2017","unstructured":"Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, Investigators BS (2017) Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 5:568\u2013576","journal-title":"Lancet Respir Med"},{"key":"849_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/cea.12244","volume":"44","author":"H Neighbour","year":"2014","unstructured":"Neighbour H, Boulet LP, Lemiere C, Sehmi R, Leigh R, Sousa AR, Martin J, Dallow N, Gilbert J, Allen A, Hall D, Nair P (2014) Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 44:508\u2013516","journal-title":"Clin Exp Allergy"},{"key":"849_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2222.2011.03813.x","volume":"42","author":"N Barnes","year":"2012","unstructured":"Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T, Parker D, Payton M, Collins LP, Pettipher R, Steiner J, Perkins CM (2012) A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 42:38\u201348","journal-title":"Clin Exp Allergy"},{"key":"849_CR45","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/all.12451","volume":"69","author":"R Pettipher","year":"2014","unstructured":"Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baillet M, Steiner J, Bell J, Payton MA (2014) Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 69:1223\u20131232","journal-title":"Allergy"},{"issue":"1","key":"849_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","volume":"9","author":"CE Brightling","year":"2020","unstructured":"Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, Maitra S, Lawrence D, Brockhaus F, Lehmann T, Brindicci C, Knorr B, Bleecker ER (2020) Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med 9(1):43\u201356","journal-title":"Lancet Respir Med"},{"key":"849_CR47","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaci.2018.05.003","volume":"143","author":"M Grozdanovic","year":"2019","unstructured":"Grozdanovic M, Laffey KG, Abdelkarim H, Hitchinson B, Harijith A, Moon HG, Park GY, Rousslang LK, Masterson JC, Furuta GT, Tarasova NI, Gaponenko V, Ackerman SJ (2019) Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness. J Allergy Clin Immunol 143:669\u2013680","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR48","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1165\/ajrcmb.17.3.2733","volume":"17","author":"EM Minshall","year":"1997","unstructured":"Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q (1997) Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 17:326\u2013333","journal-title":"Am J Respir Cell Mol Biol"},{"key":"849_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2015.06.012","volume":"167","author":"ZJ Shen","year":"2015","unstructured":"Shen ZJ, Hu J, Esnault S, Dozmorov I, Malter JS (2015) RNA Seq profiling reveals a novel expression pattern of TGF-beta target genes in human blood eosinophils. Immunol Lett 167:1\u201310","journal-title":"Immunol Lett"},{"key":"849_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, investigators Bs (2019) Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 7:46\u201359","journal-title":"Lancet Respir Med"},{"key":"849_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/thx.2004.039271","volume":"61","author":"A Dijkstra","year":"2006","unstructured":"Dijkstra A, Vonk JM, Jongepier H, Koppelman GH, Schouten JP, ten Hacken NH, Timens W, Postma DS (2006) Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 61:105\u2013110","journal-title":"Thorax"},{"key":"849_CR52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/thx.2004.037978","volume":"61","author":"P Lange","year":"2006","unstructured":"Lange P, Scharling H, Ulrik CS, Vestbo J (2006) Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 61:100\u2013104","journal-title":"Thorax"},{"key":"849_CR53","doi-asserted-by":"crossref","unstructured":"Aceves SS, Chen D, Newbury RO, Dohil R, Bastian JF, Broide DH (2010) Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-beta1, and increase esophageal smooth muscle contraction. J Allergy Clin Immunol 126:1198\u20131204","DOI":"10.1016\/j.jaci.2010.08.050"},{"key":"849_CR54","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC (2017) Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 377:1613\u20131629","journal-title":"N Engl J Med"},{"key":"849_CR55","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","volume":"198","author":"E Brenard","year":"2020","unstructured":"Brenard E, Pilette C, Dahlqvist C, Colinet B, Schleich F, Roufosse F, Froidure A (2020) Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia. Lung 198:355\u2013360","journal-title":"Lung"},{"key":"849_CR56","first-page":"101062","volume":"30","author":"T Izumo","year":"2020","unstructured":"Izumo T, Kuse N, Awano N, Tone M, Jo T, Yoshimura H, Minami J, Takada K, Muto Y, Fujimoto K, Inomata M (2020) Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia. Respir Med Case Rep 30:101062","journal-title":"Respir Med Case Rep"},{"key":"849_CR57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.alit.2020.07.005","volume":"70","author":"S Yazawa","year":"2021","unstructured":"Yazawa S, Toyoshima M, Koda K, Suda T (2021) Benralizumab as initial treatment for chronic eosinophilic pneumonia. Allergol Int 70:140\u2013142","journal-title":"Allergol Int"},{"key":"849_CR58","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ, Team EMS (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921\u20131932","journal-title":"N Engl J Med"},{"key":"849_CR59","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","volume":"146","author":"F Roufosse","year":"2020","unstructured":"Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ, group HESMs (2020) Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol 146:1397\u20131405","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","volume":"125","author":"JE Kahn","year":"2010","unstructured":"Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, Bletry O (2010) Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 125:267\u2013270","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR61","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME (2010) Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 125:1336\u20131343","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR62","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B (2011) Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 155:341\u2013343","journal-title":"Ann Intern Med"},{"issue":"20","key":"849_CR63","first-page":"31104-1","volume":"S2213-2198","author":"VP Guntur","year":"2020","unstructured":"Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, Kolakowski C, Strand MJ, Wechsler ME (2020) Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract S2213-2198(20):31104-1","journal-title":"J Allergy Clin Immunol Pract"},{"key":"849_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/ehm.11.81","volume":"5","author":"P Valent","year":"2012","unstructured":"Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Sotlar K, Butterfield JH, Cerny-Reiterer S, Mayerhofer M, Vandenberghe P, Haferlach T, Bochner BS, Gotlib J, Horny HP, Simon HU, Klion AD (2012) Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 5:157\u2013176","journal-title":"Expert Rev Hematol"},{"key":"849_CR65","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358:1215\u20131228","journal-title":"N Engl J Med"},{"key":"849_CR66","doi-asserted-by":"crossref","unstructured":"Roufosse F, de Lavareille A, Schandene L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A (2010) Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 126:828\u2013835","DOI":"10.1016\/j.jaci.2010.06.049"},{"key":"849_CR67","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","volume":"131","author":"FE Roufosse","year":"2013","unstructured":"Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD (2013) Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 131:461\u2013467","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR68","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","volume":"103","author":"AD Klion","year":"2004","unstructured":"Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB (2004) Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103:2939\u20132941","journal-title":"Blood"},{"key":"849_CR69","doi-asserted-by":"crossref","unstructured":"Ogbogu PU, Klion AD (2015) Hypereosinophilic disorders. J Allergy Clin Immunol Pract 3:304\u2013305","DOI":"10.1016\/j.jaip.2014.09.024"},{"key":"849_CR70","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","volume":"5","author":"FL Kuang","year":"2017","unstructured":"Kuang FL, Klion AD (2017) Biologic agents for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol Pract 5:1502\u20131509","journal-title":"J Allergy Clin Immunol Pract"},{"key":"849_CR71","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1182\/asheducation-2018.1.326","volume":"2018","author":"A Klion","year":"2018","unstructured":"Klion A (2018) Hypereosinophilic syndrome: approach to treatment in the era of precision medicine. Hematol Am Soc Hematol Educ Program 2018:326\u2013331","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"849_CR72","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","volume":"6","author":"P Khoury","year":"2018","unstructured":"Khoury P, Abiodun AO, Holland-Thomas N, Fay MP, Klion AD (2018) Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids. J Allergy Clin Immunol Pract 6:190\u2013195","journal-title":"J Allergy Clin Immunol Pract"},{"key":"849_CR73","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","volume":"124","author":"PU Ogbogu","year":"2009","unstructured":"Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD (2009) Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124:1319\u20131325","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR74","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","volume":"6","author":"FL Kuang","year":"2018","unstructured":"Kuang FL, Fay MP, Ware J, Wetzler L, Holland-Thomas N, Brown T, Ortega H, Steinfeld J, Khoury P, Klion AD (2018) Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. J Allergy Clin Immunol Pract 6:1518\u20131527","journal-title":"J Allergy Clin Immunol Pract"},{"key":"849_CR75","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","volume":"12","author":"ME Cudkowicz","year":"2013","unstructured":"Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA, investigators E (2013) Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 12:1059\u20131067","journal-title":"Lancet Neurol"},{"key":"849_CR76","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","volume":"63","author":"SI Dworetzky","year":"2017","unstructured":"Dworetzky SI, Hebrank GT, Archibald DG, Reynolds IJ, Farwell W, Bozik ME (2017) The targeted eosinophil-lowering effects of dexpramipexole in clinical studies. Blood Cells Mol Dis 63:62\u201365","journal-title":"Blood Cells Mol Dis"},{"key":"849_CR77","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","volume":"132","author":"SR Panch","year":"2018","unstructured":"Panch SR, Bozik ME, Brown T, Makiya M, Prussin C, Archibald DG, Hebrank GT, Sullivan M, Sun X, Wetzler L, Ware J, Fay MP, Dunbar CE, Dworetzky SI, Khoury P, Maric I, Klion AD (2018) Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood 132:501\u2013509","journal-title":"Blood"},{"key":"849_CR78","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4168\/aair.2021.13.1.8","volume":"13","author":"BS Bochner","year":"2021","unstructured":"Bochner BS, Stevens WW (2021) Biology and function of eosinophils in chronic rhinosinusitis with or without nasal polyps. Allergy, Asthma Immunol Res 13:8\u201322","journal-title":"Allergy, Asthma Immunol Res"},{"key":"849_CR79","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","volume":"118","author":"P Gevaert","year":"2006","unstructured":"Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, Holtappels G, Tavernier J, van Cauwenberge P, Bachert C (2006) Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118:1133\u20131141","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR80","doi-asserted-by":"crossref","unstructured":"Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, Durham SR, Cornet ME, Kariyawasam HH, Gilbert J, Austin D, Maxwell AC, Marshall RP, Fokkens WJ (2017) Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 140:1024\u20131031","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"849_CR81","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, De Ruyck N, Blomme K, Sousa AR, Marshall RP, Bachert C (2011) Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 128:989\u2013995","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR82","doi-asserted-by":"publisher","first-page":"E61","DOI":"10.1002\/lary.27564","volume":"129","author":"TM Laidlaw","year":"2019","unstructured":"Laidlaw TM, Prussin C, Panettieri RA, Lee S, Ferguson BJ, Adappa ND, Lane AP, Palumbo ML, Sullivan M, Archibald D, Dworetzky SI, Hebrank GT, Bozik ME (2019) Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size. Laryngoscope 129:E61\u2013E66","journal-title":"Laryngoscope"},{"key":"849_CR83","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","volume":"118","author":"ML Stein","year":"2006","unstructured":"Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assa'ad AH, Rothenberg ME (2006) Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118:1312\u20131319","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR84","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/gut.2009.178558","volume":"59","author":"A Straumann","year":"2010","unstructured":"Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59:21\u201330","journal-title":"Gut"},{"key":"849_CR85","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","volume":"141","author":"AH Assa'ad","year":"2011","unstructured":"Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS (2011) An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141:1593\u20131604","journal-title":"Gastroenterology"},{"key":"849_CR86","doi-asserted-by":"crossref","unstructured":"Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, O'Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA (2012) Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 129:456\u2013463","DOI":"10.1016\/j.jaci.2011.11.044"},{"key":"849_CR87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaci.2010.04.029","volume":"126","author":"S Conus","year":"2010","unstructured":"Conus S, Straumann A, Bettler E, Simon HU (2010) Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis. J Allergy Clin Immunol 126:175\u2013177","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR88","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/all.12096","volume":"68","author":"A Straumann","year":"2013","unstructured":"Straumann A, Hoesli S, Bussmann C, Stuck M, Perkins M, Collins LP, Payton M, Pettipher R, Hunter M, Steiner J, Simon HU (2013) Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 68:375\u2013385","journal-title":"Allergy"},{"key":"849_CR89","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","volume":"135","author":"ME Rothenberg","year":"2015","unstructured":"Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 135:500\u2013507","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR90","doi-asserted-by":"crossref","unstructured":"Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, Schoepfer AM, Safroneeva E, Rothenberg ME, Falk GW, Assouline-Dayan Y, Zhao Q, Chen Z, Swanson BN, Pirozzi G, Mannent L, Graham NMH, Akinlade B, Stahl N, Yancopoulos GD, Radin A (2020) Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology 158:111\u2013122","DOI":"10.1053\/j.gastro.2019.09.042"},{"key":"849_CR91","doi-asserted-by":"crossref","unstructured":"Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A, Straumann A, Safroneeva E, Rodriguez C, Minton N, Hua SY, Hirano I (2020) Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 19(3):473\u2013483","DOI":"10.1016\/j.cgh.2020.03.036"},{"key":"849_CR92","doi-asserted-by":"crossref","unstructured":"Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, Straumann A, Safroneeva E, Grimm M, Smith H, Tompkins CA, Woo A, Peach R, Frohna P, Gujrathi S, Penenberg DN, Li C, Opiteck GJ, Olson A, Aranda R, Rothenberg ME, Dellon ES, Group HS (2019) RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology 156:592\u2013603","DOI":"10.1053\/j.gastro.2018.10.051"},{"key":"849_CR93","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nri3737","volume":"14","author":"MS Macauley","year":"2014","unstructured":"Macauley MS, Crocker PR, Paulson JC (2014) Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 14:653\u2013666","journal-title":"Nat Rev Immunol"},{"key":"849_CR94","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC (2020) Siglecs as immune cell checkpoints in disease. Annu Rev Immunol 38:365\u2013395","journal-title":"Annu Rev Immunol"},{"key":"849_CR95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/JLB.2MR0120-352RR","volume":"108","author":"JA O'Sullivan","year":"2020","unstructured":"O'Sullivan JA, Chang AT, Youngblood BA, Bochner BS (2020) Eosinophil and mast cell Siglecs: from biology to drug target. J Leukoc Biol 108:73\u201381","journal-title":"J Leukoc Biol"},{"key":"849_CR96","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cells10010019","volume":"10","author":"BA Youngblood","year":"2021","unstructured":"Youngblood BA, Leung J, Falahati R, Williams J, Schanin J, Brock EC, Singh B, Chang AT, O'Sullivan JA, Schleimer RP, Tomasevic N, Bebbington CR, Bochner BS (2021) Discovery, function, and therapeutic targeting of Siglec-8. Cells 10:19","journal-title":"Cells"},{"key":"849_CR97","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","volume":"383","author":"ES Dellon","year":"2020","unstructured":"Dellon ES, Peterson KA, Murray JA, Falk GW, Gonsalves N, Chehade M, Genta RM, Leung J, Khoury P, Klion AD, Hazan S, Vaezi M, Bledsoe AC, Durrani SR, Wang C, Shaw C, Chang AT, Singh B, Kamboj AP, Rasmussen HS, Rothenberg ME, Hirano I (2020) Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med 383:1624\u20131634","journal-title":"N Engl J Med"},{"key":"849_CR98","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1126\/science.1201475","volume":"332","author":"D Wu","year":"2011","unstructured":"Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM (2011) Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332:243\u2013247","journal-title":"Science"},{"key":"849_CR99","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20121964","volume":"210","author":"AB Molofsky","year":"2013","unstructured":"Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, Mohapatra A, Chawla A, Locksley RM (2013) Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med 210:535\u2013549","journal-title":"J Exp Med"},{"key":"849_CR100","first-page":"120","volume":"74","author":"S Altrichter","year":"2019","unstructured":"Altrichter S, Staubach P, Pasha M, Rasmussen H, Singh B, Chang A, Bernstein J, Siebenhaar F, Maurer M (2019) Efficacy and safety data of AK002, an anti-Siglec-8 monoclonal antibody, in patients with multiple forms of uncontrolled chronic urticaria (CU): Results from an open- label phase 2a study. Allergy 74:120 (abstr)","journal-title":"Allergy"},{"key":"849_CR101","doi-asserted-by":"publisher","first-page":"AB185","DOI":"10.1016\/j.jaci.2019.12.323","volume":"145","author":"HT Levine","year":"2020","unstructured":"Levine HT, Tauber J, Nguyen Q, Anesi SD, Chang P, Berdy GJ, Lin C, Chu DS, Kantor AM, Rasmussen HS, Singh B, Chang AT, Kamboj AP, Jeng BH, Jhanji V, Foster CS (2020) Phase 1b study of AK002, an anti-Siglec-8 monoclonal antibody, in patients with severe allergic conjunctivitis (KRONOS Study). J Allergy Clin Immunol 145:AB185 (abstr)","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR102","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1056\/NEJMc2016395","volume":"383","author":"JA Bernstein","year":"2020","unstructured":"Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D (2020) Benralizumab for chronic spontaneous urticaria. N Engl J Med 383:1389\u20131391","journal-title":"N Engl J Med"},{"key":"849_CR103","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/all.14050","volume":"75","author":"EG Kang","year":"2020","unstructured":"Kang EG, Narayana PK, Pouliquen IJ, Lopez MC, Ferreira-Cornwell MC, Getsy JA (2020) Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis. Allergy 75:950\u2013953","journal-title":"Allergy"},{"key":"849_CR104","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","volume":"75","author":"D Simon","year":"2020","unstructured":"Simon D, Yousefi S, Cazzaniga S, Burgler C, Radonjic S, Houriet C, Heidemeyer K, Klotgen HW, Kozlowski E, Borradori L, Simon HU (2020) Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy 75:669\u2013672","journal-title":"Allergy"},{"key":"849_CR105","doi-asserted-by":"crossref","unstructured":"Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M (2019) Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther 41:2041\u20132056","DOI":"10.1016\/j.clinthera.2019.07.007"},{"key":"849_CR106","doi-asserted-by":"crossref","unstructured":"Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H (2019) Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 143:1742\u20131751","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"849_CR107","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","volume":"5","author":"K Murphy","year":"2017","unstructured":"Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, Zangrilli J, Castro M (2017) Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract 5:1572\u20131581","journal-title":"J Allergy Clin Immunol Pract"},{"key":"849_CR108","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/crj.12998","volume":"13","author":"AK Mishra","year":"2019","unstructured":"Mishra AK, Sahu KK, James A (2019) Disseminated herpes zoster following treatment with benralizumab. Clin Respir J 13:189\u2013191","journal-title":"Clin Respir J"},{"key":"849_CR109","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaci.2015.10.032","volume":"137","author":"HJ Kwon","year":"2016","unstructured":"Kwon HJ, Bang DW, Kim EN, Wi CI, Yawn BP, Wollan PC, Lahr BD, Ryu E, Juhn YJ (2016) Asthma as a risk factor for zoster in adults: a population-based case-control study. J Allergy Clin Immunol 137:1406\u20131412","journal-title":"J Allergy Clin Immunol"},{"key":"849_CR110","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/JAA.S172338","volume":"11","author":"PL Zeitlin","year":"2018","unstructured":"Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, Goldman M, investigators As (2018) Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial. J Asthma Allergy 11:181\u2013192","journal-title":"J Asthma Allergy"},{"issue":"20","key":"849_CR111","first-page":"31335-0","volume":"S2213-2198","author":"S Manetz","year":"2020","unstructured":"Manetz S, Maric I, Brown T, Kuang FL, Wetzler L, Battisto E, Klion AD (2020) Successful pregnancy in the setting of eosinophil depletion by benralizumab. J Allergy Clin Immunol Pract S2213-2198(20):31335-0","journal-title":"J Allergy Clin Immunol Pract"},{"key":"849_CR112","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","volume":"20","author":"S Grisaru-Tal","year":"2020","unstructured":"Grisaru-Tal S, Itan M, Klion AD, Munitz A (2020) A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer 20:594\u2013607","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"849_CR113","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ajcp\/aqaa227","volume":"155","author":"RL King","year":"2020","unstructured":"King RL, Tan B, Craig FE, George TI, Horny HP, Kelemen K, Orazi A, Reichard KK, Rimsza LM, Wang SA, Zamo A, Quintanilla-Martinez L (2020) Reactive eosinophil proliferations in tissue and the lymphocytic variant of hypereosinophilic syndrome. Am J Clin Pathol 155:211\u2013238","journal-title":"Am J Clin Pathol"},{"key":"849_CR114","first-page":"1086","volume":"100","author":"G Lefevre","year":"2015","unstructured":"Lefevre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Grardel N, Poulain S, Staumont-Salle D, Seneschal J, Salles G, Ghomari K, Terriou L, Leclech C, Morati-Hafsaoui C, Morschhauser F, Lambotte O, Ackerman F, Trauet J, Geffroy S, Dumezy F, Capron M, Roche-Lestienne C, Taieb A, Hatron PY, Dubucquoi S, Hachulla E, Prin L, Labalette M, Launay D, Preudhomme C, Kahn JE, French Eosinophil N (2015) CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica 100:1086\u20131095","journal-title":"Haematologica"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-021-00849-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T01:19:07Z","timestamp":1675214347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-021-00849-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s00281-021-00849-w","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"10 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kuang has no conflict of interest to declare. Dr. Bochner receives publication-related royalty payments from Elsevier and UpToDate. He receives remuneration for consulting services (Glaxo SmithKline, Sanofi\/Regeneron) and for serving on the scientific advisory board of Third Harmonic Bio, Inc. and Allakos, Inc. He also own stock in Allakos. Dr. Bochner is a co-inventor on existing Siglec-8\u2013related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. Dr. Bochner is a co-founder of Allakos, Inc. which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}